Skip to the page
pepts.wiki

We are not doctors and nothing here is medical advice. Always consult a medical professional first. Why we say this

Licensed medicineStub

Melanotan I

Melanocortin-1 receptor agonist (afamelanotide)

A linear analogue of alpha-MSH. As afamelanotide it is licensed as an implant for the light sensitivity of erythropoietic protoporphyria.

Reconstitution calculator

At a glance

Licensed medicine

A regulator has licensed it for at least one use, in at least one country. That says nothing about uses outside the license.

This page is a stub

The wiki has this compound's identity from the My-Pepts library, its standing, and what PubMed holds for it. The article, with its studies read and cited, is not written yet. Until it is, the counts below say how much research exists, not what it found.

How strong is the evidence

How far it has climbed

Every medicine climbs the same ladder. Most compounds never reach the top, and where one stands says how much its claims can carry.

  1. Licensed medicine: Melanotan I

    A regulator has reviewed the trials and licensed it for a named use.

  2. Phase 3

    Large randomized trials, often thousands of people, against placebo or a standard treatment.

  3. Phase 2

    Mid-sized trials that measure dose against effect in people with the condition.

  4. Phase 1 and early human studies

    First studies in people: safety, and how the body handles it.

  5. Cells and animals

    Laboratory and animal work. An animal result is not a result in people.

124
papers on PubMed
87
of them in people
5
randomized trials
48
reviews

A count says how much has been published, not what it found. Counted on PubMed: 2026-11-16

Handling and reconstitution

From powder to a measured sample

The same four steps for any lyophilized vial. Laboratory handling, not use in a person.

  1. 1. Read the vial

    The label gives the mass of peptide in the vial, in milligrams. That number is the start of every calculation.

  2. 2. Add the diluent

    A measured volume of diluent goes in slowly, down the glass. Swirl gently; shaking can damage a peptide.

  3. 3. Work out the strength

    Concentration is mass divided by volume: 10 mg in 2 mL is 5 mg per mL.

  4. 4. Measure the sample

    Volume is the mass wanted divided by the concentration. On a U-100 syringe, 1 mL is 100 units.

The calculator below does the arithmetic and shows its working.

As powder

General practice for lyophilized peptides: keep the sealed vial frozen or refrigerated, dry and away from light, and follow the supplier's certificate of analysis.

In solution

Once in solution a peptide is kept refrigerated and used within the period the supplier states. A vial drawn from more than once needs a preserved diluent such as bacteriostatic water.

This is general practice for lyophilized peptides, not data on Melanotan I itself. The batch's certificate of analysis and the supplier's sheet are the facts to go by. More on storage

Reconstitution calculator

Opens on vial sizes common for research peptides. Change any number. How the arithmetic works

Draw to

10 units

0.1 mL on a U-100 syringe

Concentration
2.5 mg/mL
Each unit holds
25 mcg
Samples in the vial
20
Sample
250 mcg

5 mg in 2 mL is 2.5 mg/mL. 250 mcg of that is 0.1 mL, which reads as 10 units. This is arithmetic for a vial of Melanotan I; no amount here is a recommendation.

Melanotan I: on PubMed

What PubMed held for Melanotan I on November 16, 2026. A count says how much a compound has been studied, not what the studies found: how to read these numbers.

124
papers
87
in humans
13
clinical trials
5
randomized trials
2012: 5 papers122013: 6 papers2014: 5 papers142015: 8 papers2016: 6 papers162017: 8 papers2018: 3 papers182019: 4 papers2020: 9 papers202021: 9 papers2022: 5 papers222023: 17 papers2024: 14 papers242025: 13 papers2026: 12 papers so far26
Papers per year, 2012 to 2026. The most in one year: 17.

Most relevant on PubMed

Listed by PubMed's own relevance ranking, trials and reviews first. The wiki has not read these into the article unless they are also among its sources.

  1. Afamelanotide for Erythropoietic Protoporphyria

    Randomized trialLangendonk JG, Balwani M, Anderson KE, et al. The New England journal of medicine, 2015. PMID 26132941

  2. Efficacy of the melanocortin analogue Nle4-D-Phe7-α-melanocyte-stimulating hormone in the treatment of patients with Hailey-Hailey disease

    TrialBiolcati G, Aurizi C, Barbieri L, et al. Clinical and experimental dermatology, 2014. PMID 24256215

  3. Beneficial effects of the melanocortin analogue Nle4-D-Phe7-α-MSH in acne vulgaris

    TrialBöhm M, Ehrchen J, Luger TA Journal of the European Academy of Dermatology and Venereology : JEADV, 2014. PMID 22845050

  4. Evaluation of the immunogenicity of the synthetic α-melanocyte-stimulating hormone (α-MSH) analogue afamelanotide ([Nle4-D-Phe7]-α-MSH, Scenesse®) in erythropoietic protoporphyria patients by ELISA detecting both anti-afamelanotide and anti-α-MSH antibodies

    TrialLengweiler S, Kreim S, Barman-Aksözen J, et al. Skin pharmacology and physiology, 2015. PMID 25402764

  5. Mitigating photosensitivity of erythropoietic protoporphyria patients by an agonistic analog of alpha-melanocyte stimulating hormone

    TrialHarms JH, Lautenschlager S, Minder CE, et al. Photochemistry and photobiology, 2009. PMID 19656325

  6. Adjunctive use of Polypodium leucotomos extract in patients with erythropoietic protoporphyria: An exploratory study

    TrialShetty N, Quiñonez RL, Ceresnie MS, et al. Photochemistry and photobiology, 2026. PMID 41766687

  7. [Undesirable pigmentation]

    ReviewBayerl C Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 2015. PMID 26315100

  8. Vitiligo: Pathogenesis and New and Emerging Treatments

    ReviewPerez-Bootello J, Cova-Martin R, Naharro-Rodriguez J, et al. International journal of molecular sciences, 2023. PMID 38139134

Search used: (afamelanotide[tiab] OR "melanotan I"[tiab] OR "melanotan-1"[tiab]). Run it on PubMed

Research links

Also in Skin and longevity